The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a sm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xin Xie, Jingwen Lv, Wei Zhu, Chao Tian, Jingfeng Li, Jiajia Liu, Hua Zhou, Chunyang Sun, Zongfeng Hu, Xiaopeng Li
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Oncolytic virus HSV-1 IL-12 PD-1 antibody Cancer immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fa02f758bc344d9cb6d0c4f44a8890f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa02f758bc344d9cb6d0c4f44a8890f4
record_format	dspace
spelling	oai:doaj.org-article:fa02f758bc344d9cb6d0c4f44a8890f42021-11-20T05:05:21ZThe combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy1936-523310.1016/j.tranon.2021.101287https://doaj.org/article/fa02f758bc344d9cb6d0c4f44a8890f42022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1936523321002783https://doaj.org/toc/1936-5233Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a small number of patients benefit from the treatment. Oncolytic viruses exert anti-tumor effects by regulating the tumor microenvironment and affecting multiple steps of tumor immune circulation. In this study, we engineered two oncolytic viruses that express mouse anti-PD-1 antibody (VT1093M) or mouse IL-12 (VT1092M). We found that both oncolytic viruses showed significant anti-tumor effects in a murine CT26 colon adenocarcinoma model. Importantly, the intratumoral combined injection with VT1092M and VT1093M inhibited growth of the primary tumor, prevented growth of the contralateral untreated tumor, produced a vaccine-like response, activated antigen-specific T cell responses and prolonged the overall survival rate of mice. These results indicate that combination therapy with the engineered oncolytic virus may represent a potent immunotherapy strategy for cancer patients, especially those resistant to PD-1/PD-L1 blockade therapy.Xin XieJingwen LvWei ZhuChao TianJingfeng LiJiajia LiuHua ZhouChunyang SunZongfeng HuXiaopeng LiElsevierarticleOncolytic virusHSV-1IL-12PD-1 antibodyCancer immunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101287- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Oncolytic virus HSV-1 IL-12 PD-1 antibody Cancer immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Oncolytic virus HSV-1 IL-12 PD-1 antibody Cancer immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xin Xie Jingwen Lv Wei Zhu Chao Tian Jingfeng Li Jiajia Liu Hua Zhou Chunyang Sun Zongfeng Hu Xiaopeng Li The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
description	Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a small number of patients benefit from the treatment. Oncolytic viruses exert anti-tumor effects by regulating the tumor microenvironment and affecting multiple steps of tumor immune circulation. In this study, we engineered two oncolytic viruses that express mouse anti-PD-1 antibody (VT1093M) or mouse IL-12 (VT1092M). We found that both oncolytic viruses showed significant anti-tumor effects in a murine CT26 colon adenocarcinoma model. Importantly, the intratumoral combined injection with VT1092M and VT1093M inhibited growth of the primary tumor, prevented growth of the contralateral untreated tumor, produced a vaccine-like response, activated antigen-specific T cell responses and prolonged the overall survival rate of mice. These results indicate that combination therapy with the engineered oncolytic virus may represent a potent immunotherapy strategy for cancer patients, especially those resistant to PD-1/PD-L1 blockade therapy.
format	article
author	Xin Xie Jingwen Lv Wei Zhu Chao Tian Jingfeng Li Jiajia Liu Hua Zhou Chunyang Sun Zongfeng Hu Xiaopeng Li
author_facet	Xin Xie Jingwen Lv Wei Zhu Chao Tian Jingfeng Li Jiajia Liu Hua Zhou Chunyang Sun Zongfeng Hu Xiaopeng Li
author_sort	Xin Xie
title	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
title_short	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
title_full	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
title_fullStr	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
title_full_unstemmed	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
title_sort	combination therapy of oncolytic hsv-1 armed with anti-pd-1 antibody and il-12 enhances anti-tumor efficacy
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/fa02f758bc344d9cb6d0c4f44a8890f4
work_keys_str_mv	AT xinxie thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT jingwenlv thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT weizhu thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT chaotian thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT jingfengli thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT jiajialiu thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT huazhou thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT chunyangsun thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT zongfenghu thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT xiaopengli thecombinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT xinxie combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT jingwenlv combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT weizhu combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT chaotian combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT jingfengli combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT jiajialiu combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT huazhou combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT chunyangsun combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT zongfenghu combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy AT xiaopengli combinationtherapyofoncolytichsv1armedwithantipd1antibodyandil12enhancesantitumorefficacy
_version_	1718419635214221312

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

Ejemplares similares